Default company panoramic image

Cordgenics LLC

Biotech in Phase 1 trials. Technology expands cancer stem cells to provide diagnostic of best personalized therapy. Product launch in 2015.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Huntington, WV, USA
  • Currency USD
  • Founded April 2010
  • Employees 5
  • Website

Company Summary

Cordgenics is a clinical stage (Phase l) biotech with proprietary technology (patents applied for) that will provide cancer patients with a personalized diagnostic as to which chemotherapy agents (or "cocktail") will kill the progenitor "stem" cells that cause cancer to return. Unlike other approaches, cells replicated by the Co. are identical to the originals w/o using harmful growth factors. We expect to launch a commercial product in 2015.


  • Default avatar
    Dan Menichella

    20 year healthcare/biotech professional. Strong background in negotiating licenses, JV's, and partnering arrangements leading to operating and royalty-based revenues. Built strong professional teams. Sold and bought operating divisions and companies, took one firm public. Five years at Merck; 4 at Talecris Biopharmaceuticals (Cerburus owned); former President, MorphySys USA. BA, Harvard; MBA UNC-Chapel Hill

  • Default avatar
    Jim Phelps

    Senior financial professional with 25 years experience in finance, law, and fast-growing companies. Established accounting and control systems for early stage tech companies as CFO and Board member. Solid background in VC finance, including biotech companies involved in stem cells. Strong presentation and analytical skills. Core prof'l experience as Wall Street atty and investment banker. BA, Johns Hopkins; JD, UCLA; MBA, Stanford.

  • Default avatar
    Pier Paolo Claudio, M.D., Ph.D.
    Chief Scientific Officer

    Dr. Claudio has 20 years of experience in cancer research and targeted therapy. He has published over 120 scientific articles and holds numerous patents.

    He is Assoc. Professor, Marshall Univ School of Medicine, and also serves as Dir. of the Translational Genomics Research Institute. He graduated from the Univ. of Naples (Italy) and has been an Assoc. Professor at Jefferson Univ. Med School, and Director, Temple Univ. Molecular Therapy Prog

  • Default avatar
    Jagan Valluri, Ph.D.
    Vice President

    Dr. Valluri is Professor of Cellular Biology and Integrative Medicine at Marshall University. He has over 21 years of research experience in cell culture, production of anticancer bio-molecules,and bench-top fermenters. Dr. Valluri has consulted to NASA and U.S. Army Corps of Engineers and is the author of several journal articles, book chapters and co-inventor on 2 patent apps. He earned his Ph.D. in Molecular Biology from Texas A & M Univ.


  • Default avatar
    Stites & Harbison, (Louisville, KY) -- Terry Wright, Esq. (Intellectual Property)

Previous Investors

  • Default avatar
    To date, the Company has primarily been financed by grants and through Marshall University.